Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Avanir Pharmaceuticals Inc. (NASDAQ: AVNR) shares increased 1.56 percent to close at $4.57 a share Tuesday. The stock traded between $4.55 and $4.98 on volume of 4.61 million shares traded. The company announced that it has entered into an exclusive, multi-year agreement with Merck to promote Merck’s type-2 diabetes drug Januvia in the long-term care institutional setting in the United States. Shares of Avanir Pharmaceuticals have gained approximately 75.0 percent year-to-date.
Get more information on Avanir Pharmaceuticals and free access to the in-depth equity report at:
Given Imaging Ltd. (NASDAQ: GIVN) shares spiked 6.49 percent to close at $17.39 a share Tuesday. The stock traded between $17.01 and $17.59 on volume of 350,580 shares traded. The company announced that its third-generation PillCam SB 3 has received clearance from the FDA to detect and monitor small bowel abnormalities associated with Crohn’s and other diseases.
Get more information on Given Imaging and free access to the in-depth equity report at:
Insys Therapeutics Inc. (NASDAQ: INSY) shares surged 22.26 percent to close at $21.86 a share Tuesday. The stock traded between $18.80 and $23.49 on volume of 623,036 shares traded. The company reported a net income of $4.5 million for the second quarter of 2013, compared to a net loss of $6.4 million a year ago. Shares of Insys Therapeutics have gained approximately 180.0 percent year-to-date.
Get more information on Insys Therapeutics and free access to the in-depth equity report at:
Osiris Therapeutics, Inc. (NASDAQ: OSIR) shares soared 138.65 percent to close at $25.44 a share Tuesday. The stock traded between $16.55 and $25.90 on volume of 9.05 million shares traded. The company announced Grafix, a stem cell treatment for acute and chronic wound repair, demonstrated overwhelming efficacy in a landmark stem cell study for the treatment of diabetic foot ulcers.
Get more information on Osiris Therapeutics and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities
Leave a comment...